

REFINITIV

DELTA REPORT

10-Q

SAIC - SCIENCE APPLICATIONS INTE

10-Q - AUGUST 02, 2024 COMPARED TO 10-Q - MAY 03, 2024

The following comparison report has been automatically generated

TOTAL DELTAS 637

 CHANGES 121
 DELETIONS 220
 ADDITIONS 296

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **May 3, 2024** **August 2, 2024**

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 001-35832

Science Applications International Corporation

(Exact name of registrant as specified in its charter)

Delaware

46-1932921

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

12010 Sunset Hills Road, Reston, Virginia

20190

(Address of principal executive offices)

(Zip Code)

(703) 676-4300

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value \$.0001 per share

SAIC

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares issued and outstanding of the registrant's common stock as of May 24, 2024 August 23, 2024 was as follows:

51,231,156 49,520,103 shares of common stock (\$0.0001 par value per share)

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

FORM 10-Q

TABLE OF CONTENTS

	<u>Page</u>
Part I	<u>Financial Information</u>
Item 1	<u>Financial Statements</u> 1
	<u>Condensed Consolidated Statements of Income</u> 1
	<u>Condensed Consolidated Statements of Comprehensive Income</u> 2
	<u>Condensed Consolidated Balance Sheets</u> 3
	<u>Condensed Consolidated Statements of Equity</u> 4
	<u>Condensed Consolidated Statements of Cash Flows</u> 5
	<u>Notes to Condensed Consolidated Financial Statements</u> 6
	<u>Note 1—Business Overview and Summary of Significant Accounting Policies</u> 6
	<u>Note 2—Earnings Per Share, Share Repurchases and Dividends</u> 98
	<u>Note 3—Revenues</u> 9
	<u>Note 4—Divestitures</u> 12
	<u>Note 5—Goodwill and Intangible Assets</u> 13
	<u>Note 6—Income Taxes</u> 14
	<u>Note 7—Debt Obligations</u> 1415
	<u>Note 8—Derivative Instruments Designated as Cash Flow Hedges</u> 16
	<u>Note 9—Changes in Accumulated Other Comprehensive Income (Loss) by Component</u> 1617
	<u>Note 10—Sales of Receivables</u> 1718
	<u>Note 11—Business Segments Segments Information</u> 1718
	<u>Note 12—Legal Proceedings and Other Commitments and Contingencies</u> 1719
	<u>Note 13—Subsequent Events</u> 20
Item 2	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> 2021
Item 3	<u>Quantitative and Qualitative Disclosures About Market Risk</u> 2830
Item 4	<u>Controls and Procedures</u> 2830
Part II	<u>Other Information</u> 2931

Item 1	Legal Proceedings	2931
Item 1A	Risk Factors	2931
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds and Issuer Purchases of Equity Securities	2931
Item 3	Defaults Upon Senior Securities	2931
Item 4	Mine Safety Disclosures	2931
Item 5	Other Information	2931
Item 6	Exhibits	3032
	Signatures	3133

-i-

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)

	Three Months Ended		Six Months Ended	
			August 2, 2024	August 4, 2023
	(in millions, except per share amounts)		(in millions, except per share amounts)	
Revenues				
Cost of revenues				
Cost of revenues				
Cost of revenues				
Selling, general and administrative expenses				
Selling, general and administrative expenses				
Selling, general and administrative expenses				
(Gain) loss on divestitures, net of transaction costs				
(Gain) loss on divestitures, net of transaction costs				

(Gain) loss on divestitures, net of transaction costs
Other operating (income) expense
Other operating (income) expense
Other operating (income) expense
Operating income
Operating income
Operating income
Interest expense, net
Interest expense, net
Interest expense, net
Other (income) expense, net
Other (income) expense, net
Other (income) expense, net
Income before income taxes
Income before income taxes
Income before income taxes
Provision for income taxes
Provision for income taxes
Provision for income taxes
Net income
Net income
Net income
Earnings per share:
Earnings per share:
Earnings per share:
Basic
Basic
Basic
Diluted
Diluted
Diluted

See accompanying notes to condensed consolidated financial statements.

-1-

[Table of Contents](#)

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)

	Three Months Ended May 3, 2024	Three Months Ended May 3, 2024	Three Months Ended May 3, 2024	Six Months Ended August 2, 2024	August 4, 2023	August 2, 2024	August 4, 2023
Net income							
Other comprehensive income (loss), net of tax:							
Other comprehensive income (loss), net of tax:							
Other comprehensive income (loss), net of tax:							
Net unrealized gain (loss) on derivative instruments							
Net unrealized gain (loss) on derivative instruments							
Net unrealized gain (loss) on derivative instruments							
Total other comprehensive income (loss), net of tax							
Total other comprehensive income (loss), net of tax							
Total other comprehensive income (loss), net of tax							
Other comprehensive (loss) income, net of tax:							
Net unrealized (loss) gain on derivative instruments							
Net unrealized (loss) gain on derivative instruments							
Net unrealized (loss) gain on derivative instruments							
Total other comprehensive (loss) income, net of tax							

Comprehensive income
Comprehensive income
Comprehensive income

See accompanying notes to condensed consolidated financial statements.

-2-

[Table of Contents](#)

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

	May 3, 2024	February 2, 2024	August 2, 2024	February 2, 2024
	(in millions)			(in millions)
ASSETS	ASSETS	ASSETS	ASSETS	ASSETS
Current assets:	Current assets:	Current assets:	Current assets:	Current assets:
Cash and cash equivalents				
Receivables, net				
Prepaid expenses and other current assets				
Total current assets				
Goodwill				
Intangible assets, net				
Property, plant, and equipment (net of accumulated depreciation of \$188 million and \$184 million at May 3, 2024 and February 2, 2024, respectively)				
Property, plant, and equipment (net of accumulated depreciation of \$193 million and \$184 million at August 2, 2024 and February 2, 2024, respectively)				
Operating lease right of use assets				
Other assets				
Total assets				
LIABILITIES AND EQUITY				
LIABILITIES AND EQUITY				
LIABILITIES AND EQUITY				
Current liabilities:	Current liabilities:	Current liabilities:	Current liabilities:	Current liabilities:
Accounts payable				
Accrued payroll and employee benefits				
Other accrued liabilities				
Long-term debt, current portion				

Debt, current portion		
Total current liabilities		
Long-term debt, net of current portion		
Debt, net of current portion		
Operating lease liabilities		
Deferred income taxes		
Other long-term liabilities		
Commitments and contingencies (Note 12)	Commitments and contingencies (Note 12)	Commitments and contingencies (Note 12)
Equity:	Equity:	Equity:
Common stock, \$0.0001 par value, 1 billion shares authorized, 51 million and 52 million shares issued and outstanding as of May 3, 2024 and February 2, 2024, respectively		
Common stock, \$0.0001 par value, 1 billion shares authorized, 50 million and 52 million shares issued and outstanding as of August 2, 2024 and February 2, 2024, respectively		
Additional paid-in capital		
Retained earnings		
Accumulated other comprehensive income		
Total stockholders' equity		
Total liabilities and stockholders' equity		

See accompanying notes to condensed consolidated financial statements.

-3-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)

	Shares of common stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non- controlling interest	Total	Shares of common stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non- controlling interest	Total
(in millions)							(in millions)					
Balance at May 3, 2024												
Net income												
Issuances of stock												

Other comprehensive loss, net of tax
Cash dividends of \$0.37 per share
Stock-based compensation, net of shares withheld for taxes ⁽¹⁾
Repurchases of stock
Balance at August 2, 2024
Balance at February 2, 2024
Balance at February 2, 2024
Balance at February 2, 2024
Net income
Issuances of stock
Other comprehensive loss, net of tax
Cash dividends of \$0.74 per share
Stock-based compensation, net of shares withheld for taxes ⁽¹⁾
Repurchases of stock
Balance at August 2, 2024
Balance at February 2, 2024
Balance at February 2, 2024
Balance at May 5, 2023
Balance at May 5, 2023
Balance at May 5, 2023
Net income
Issuances of stock
Other comprehensive income, net of tax
Cash dividends of \$0.37 per share
Stock-based compensation, net of shares withheld for taxes ⁽¹⁾
Repurchases of stock
Balance at May 3, 2024
Balance at August 4, 2023
Balance at February 3, 2023
Balance at February 3, 2023
Balance at February 3, 2023
Net income
Issuances of stock
Other comprehensive loss, net of tax
Cash dividends of \$0.37 per share
Other comprehensive income, net of tax
Cash dividends of \$0.74 per share

Stock-based compensation, net of shares withheld for taxes ⁽¹⁾
Repurchases of stock
Deconsolidation of non-controlling interest
Balance at May 5, 2023
Balance at August 4, 2023

(1) During the three months ended May 3, 2024 August 2, 2024 and May 5, 2023 August 4, 2023, shares withheld for taxes related to stock-based compensation arrangements amounted to \$22 \$1 million. During the six months ended August 2, 2024 and August 4, 2023, shares withheld for taxes related to stock-based compensation arrangements amounted to \$23 million and \$19 \$20 million, respectively.

See accompanying notes to condensed consolidated financial statements.

-4-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

Cash flows from operating activities:

Cash flows from operating activities:

Cash flows from operating activities:

Net income

Net income

Net income

Adjustments to reconcile net income to net cash provided by operating activities:

Adjustments to reconcile net income to net cash provided by operating activities:

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

Depreciation and amortization

Depreciation and amortization

Deferred income taxes

Deferred income taxes

Deferred income taxes

Stock-based compensation expense

Stock-based compensation expense

Stock-based compensation expense

(Gain) loss on sale of long-lived assets

(Gain) loss on sale of long-lived assets

(Gain) loss on sale of long-lived assets

(Gain) loss on divestitures

(Gain) loss on divestitures
(Gain) loss on divestitures
Other
Other
Other
Increase (decrease) resulting from changes in operating assets and liabilities, net of the effect of divestitures:
Increase (decrease) resulting from changes in operating assets and liabilities, net of the effect of divestitures:
Increase (decrease) resulting from changes in operating assets and liabilities, net of the effect of divestitures:
Receivables
Receivables
Receivables
Prepaid expenses and other current assets
Prepaid expenses and other current assets
Prepaid expenses and other current assets
Other assets
Other assets
Other assets
Accounts payable and accrued liabilities
Accounts payable and accrued liabilities
Accounts payable and accrued liabilities
Accrued payroll and employee benefits
Accrued payroll and employee benefits
Accrued payroll and employee benefits
Income taxes payable
Income taxes payable
Income taxes payable
Operating lease assets and liabilities, net
Operating lease assets and liabilities, net
Operating lease assets and liabilities, net
Other long-term liabilities
Other long-term liabilities
Other long-term liabilities
Net cash provided by operating activities
Net cash provided by operating activities
Net cash provided by operating activities
Cash flows from investing activities:
Cash flows from investing activities:
Cash flows from investing activities:
Expenditures for property, plant, and equipment
Expenditures for property, plant, and equipment
Expenditures for property, plant, and equipment
Purchases of marketable securities
Purchases of marketable securities

Purchases of marketable securities
Sales of marketable securities
Sales of marketable securities
Sales of marketable securities
Proceeds from assets held for sale
Proceeds from assets held for sale
Proceeds from assets held for sale
Proceeds from sale of long-lived assets
Proceeds from sale of long-lived assets
Proceeds from sale of long-lived assets
Proceeds from divestitures
Proceeds from divestitures
Proceeds from divestitures
Cash divested upon deconsolidation of joint venture
Cash divested upon deconsolidation of joint venture
Cash divested upon deconsolidation of joint venture
Other
Other
Other
Net cash (used in) provided by investing activities
Net cash (used in) provided by investing activities
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Cash flows from financing activities:
Cash flows from financing activities:
Dividend payments to stockholders
Dividend payments to stockholders
Dividend payments to stockholders
Principal payments on borrowings
Principal payments on borrowings
Principal payments on borrowings
Issuances of stock
Issuances of stock
Issuances of stock
Stock repurchased and retired or withheld for taxes on equity awards
Stock repurchased and retired or withheld for taxes on equity awards
Stock repurchased and retired or withheld for taxes on equity awards
Proceeds from borrowings
Proceeds from borrowings
Proceeds from borrowings
Net cash used in financing activities
Net cash used in financing activities

Net cash used in financing activities
Net (decrease) increase in cash, cash equivalents and restricted cash
Net (decrease) increase in cash, cash equivalents and restricted cash
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Cash, cash equivalents and restricted cash at end of period
Cash, cash equivalents and restricted cash at end of period

See accompanying notes to condensed consolidated financial statements.

-5-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Note 1—Business Overview and Summary of Significant Accounting Policies:

Overview

Science Applications International Corporation (collectively, with its consolidated subsidiaries, the "Company") is a leading provider of technical, engineering and enterprise information technology ("IT") services primarily to the U.S. government. The Company integrates emerging technology securely and in real-time into mission critical operations that modernize and enable national imperatives. The Company provides these services for large, complex projects with a targeted emphasis on higher-end, differentiated technology services and solutions that accelerate and transform secure and resilient digital environments through system development, modernization, integration, and sustainment to drive enterprise and mission outcomes.

Effective February 3, 2024, the first day of fiscal 2025, the Company completed a business reorganization which replaced its previous two customer facing operating sectors with five customer facing business groups supported by the enterprise organizations, including the Innovation Factory. The Company's five business groups, which are also its operating segments, are aggregated into two reportable segments for financial reporting purposes given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. The Company's two reportable segments are the Defense and Intelligence segment and the Civilian segment.

The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the defense and intelligence departments and agencies of the United States Government.

The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy.

The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives, including IT modernization, digital engineering, artificial intelligence ("AI"), mission systems support and advisory, training and simulation, and ground vehicles support. These services include end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment and security of the customers' entire IT infrastructure.

The Company's Innovation Factory supports the operating segments by developing enterprise-class solutions which are delivered to the Company's customers as stand-alone solutions or integrated with and aligned to product offerings through the operations of the business to meet complex

customer needs and accelerate digital transformation. The Innovation Factory includes designated teams focused on AI, application development, network services, platforms and cloud, and **cyber** **cybersecurity**. It uses a highly automated, cloud-hosted tool set to rapidly build, test and deploy solutions **quickly** and works with customers to enhance solutions going forward.

Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate activities. See Note 11—Business Segments Information for additional information.

Within this report, the Company has recast historical financial information to reflect the new reportable segments. The recast historical information has no impact on the Company's previously reported condensed consolidated financial statements.

Principles of Consolidation and Basis of Presentation

References to "financial statements" refer to the condensed consolidated financial statements of the Company, which include the statements of income and comprehensive income, balance sheets, statements of equity and statements of cash flows. These financial statements were prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). All intercompany transactions and account balances within the Company have been eliminated.

-6-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Certain amounts in the prior year financial statements have been reclassified to conform to the current year presentation. Interest income was reclassified from "Other (income) expense, net" to "Interest expense, net" on the condensed consolidated statements of income, gains on divestitures, net of transaction costs were reclassified from "Other operating (income) expense" to "(Gain) loss on divestitures, net of transaction costs" on the condensed consolidated statements of income, and "Accounts Payable" is now presented separately from "Other accrued liabilities" on the condensed consolidated balance sheets. The results reported in these financial statements are not necessarily indicative of results that may be expected for the entire year and should be read in conjunction with the information contained in the Company's Annual Report on Form 10-K for the year ended February 2, 2024.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Significant estimates inherent in the preparation of the financial statements may include, but are not limited to, estimated profitability of long-term contracts, income taxes, fair value measurements, fair value of goodwill and other intangible assets, pension and defined benefit plan obligations, and contingencies. Estimates have been prepared by management on the basis of the most current and best available information at the time of estimation and actual results could differ from those estimates.

Reporting Periods

The Company utilizes a 52/53 week fiscal year ending on the Friday closest to January 31, with fiscal quarters typically consisting of 13 weeks. Fiscal 2025 began on February 3, 2024 and ends on January 31, 2025, while fiscal 2024 began on February 4, 2023 and ended on February 2, 2024.

Operating Cycle

The Company's operating cycle may be greater than one year and is measured by the average time intervening between the inception and the completion of contracts.

Derivative Instruments Designated as Cash Flow Hedges

Derivative instruments are recorded on the condensed consolidated balance sheets at fair value. Unrealized gains and losses on derivatives designated as cash flow hedges are reported in other comprehensive income (loss) and reclassified to earnings in a manner that matches the

timing of the earnings impact of the hedged transactions. Settlement amounts related to derivatives designated as cash flow hedges are presented within operating activities on the condensed consolidated statement of cash flows.

The Company's fixed interest rate swaps are considered over-the-counter derivatives, and their fair value is calculated using a standard pricing model for interest rate swaps with contractual terms for maturities, amortization and interest rates. Level 2, or market observable inputs (such as yield and credit curves), are used within the standard pricing models in order to determine fair value. The fair value is an estimate of the amount that the Company would pay or receive as of a measurement date if the agreements were transferred to a third party. See Note 8—Derivative Instruments Designated as Cash Flow Hedges for further discussion on the Company's derivative instruments designated as cash flow hedges.

Marketable Securities

Investments in marketable securities consist of equity securities, which are recorded at fair value using observable inputs such as quoted prices in active markets (Level 1). As of **May 3, 2024** **August 2, 2024** and February 2, 2024, the fair value of the Company's investments totaled **\$32 million**, **\$36 million** and **\$32 million**, respectively, and are included in "Other assets" on the condensed consolidated balance sheets. The Company's investments are primarily held in a custodial account, which includes investments to fund its deferred compensation plan liabilities.

-7-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported on the condensed consolidated balance sheets for the periods presented:

	May 3, 2024	February 2, 2024	August 2, 2024	February 2, 2024
	(in millions)	(in millions)	(in millions)	(in millions)
Cash and cash equivalents				
Restricted cash included in prepaid expenses and other current assets				
Restricted cash included in other assets				
Cash, cash equivalents and restricted cash				

Restructuring Costs

The Company periodically initiates restructuring activities to support business strategies, realign resources, and enhance its operational efficiency. Restructuring costs may include severance and other employee related termination costs, costs associated with consolidating or closing facilities and consulting costs.

Restructuring costs for the three and six months ended **May 3, 2024** **August 2, 2024** were \$2 million and \$4 million, respectively, and were primarily related to activities associated with the reorganization of its business sectors into business groups, groups and the optimization and consolidation of certain facilities. Restructuring costs for the three and six months ended **May 5, 2023** **August 4, 2023** were \$1 \$5 million and \$6 million, respectively, and were primarily associated with the optimization and consolidation of certain facilities. Restructuring costs are presented within "Selling, general and administrative expenses" on the condensed consolidated statements of income.

Investments in Equity Securities

The Company invests in certain companies that advance or develop new technologies applicable to its business. The Company also occasionally forms joint ventures as a part of its investment strategy for the purpose of bidding and executing on specific projects. Each investment is evaluated for consolidation under the variable interest entities ("VIEs") model and/or the voting interest model. The results of these investments are not material to the condensed consolidated financial statements for the periods presented.

The Company applies the equity method of accounting to its unconsolidated investments when it has the ability to exercise significant influence over the entity and recognizes its proportionate share of the entities' net income or loss within "Other operating (income) expense" on the condensed consolidated statements of income. Equity investments in entities over which the Company does not have the ability to exercise significant influence and whose securities do not have a readily determinable fair value and do not qualify to be measured at their Net Asset Value per share (or equivalent) are carried at cost or cost net of other-than-temporary impairments.

Accounting Standards Updates

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*. The standard includes amendments that enhance annual income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The standard is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments can be applied on a prospective or retrospective basis. The Company plans to adopt this standard in fiscal 2026 and is currently evaluating the impact of adoption of this standard on its **condensed consolidated financial statements and related statement disclosures**.

In November 2023, the FASB issued ASU No. 2023-07, *Segment Reporting (Topic 280, 280): Improvements to Reportable Segment Disclosures*, to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. Amongst other amendments, the standard requires annual and interim disclosures of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"), and interim disclosures about a reportable segment's profit or loss and assets that are currently required annually. This standard does not change how an entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years

-8-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt the annual disclosure in fiscal 2025 and the interim disclosure in fiscal 2026 and is currently evaluating the impact of adoption of this standard on its **condensed consolidated financial statements, statement disclosures**.

Note 2—Earnings Per Share, Share Repurchases and Dividends:

Earnings Per Share ("EPS")

Basic EPS is computed by dividing net income by the basic weighted-average number of shares outstanding. Diluted EPS is computed similarly to basic EPS, except the weighted-average number of shares outstanding is increased to include the dilutive effect of outstanding stock-based awards. The dilutive effect of outstanding stock-based awards is computed using the treasury stock method.

-8-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

The following table provides a reconciliation of the weighted-average number of shares outstanding used to compute basic and diluted EPS for the periods presented:

	Three Months Ended		Six Months Ended	
	August 2, 2024	August 4, 2023	August 2, 2024	August 4, 2023
	(in millions)	(in millions)		
Basic weighted-average number of shares outstanding				
Dilutive common share equivalents - stock options and other stock-based awards				
Dilutive common share equivalents - stock options and other stock-based awards				
Dilutive common share equivalents - stock options and other stock-based awards				
Diluted weighted-average number of shares outstanding				
Diluted weighted-average number of shares outstanding				
Diluted weighted-average number of shares outstanding				

Antidilutive stock awards excluded from the weighted-average number of shares outstanding used to compute diluted EPS for the three and six months ended **May 3, 2024** **August 2, 2024** and **May 5, 2023** **August 4, 2023** were immaterial.

Share Repurchases

The Company may repurchase shares in accordance with established repurchase plans. The Company retires its common stock upon repurchase with the excess over par value allocated to additional paid-in capital. The Company has not made any material purchases of common stock other than in connection with established share repurchase plans. In June 2022, the number of shares of the Company's common stock that may be repurchased under the Company's existing repurchase plan was increased by 8.0 million shares, bringing the total authorized shares to be repurchased under the plan to approximately 24.4 million shares. As of **May 3, 2024** **August 2, 2024**, the Company has repurchased approximately **20.9 million** **22.6 million** shares of its common stock under the plan.

Dividends

The Company declared and paid a quarterly dividend of \$0.37 per share of its common stock during the three months ended **May 3, 2024**. Subsequent to the end of the quarter, on **May 30, 2024**, the Company's Board of Directors declared a quarterly dividend of \$0.37 per share of the Company's common stock payable on **July 26, 2024** to stockholders of record on **July 12, 2024** **August 2, 2024**.

Note 3—Revenues:

Changes in Estimates on Contracts

Changes in estimates of revenues, cost of revenues or profits related to performance obligations satisfied over time are recognized in operating income in the period in which such changes are made for the inception-to-date effect of the changes. Changes in these estimates can occur routinely over the performance period for a variety of reasons, which include: changes in scope; changes in cost estimates due to unanticipated cost growth or reassessments of risks impacting costs; changes in the estimated transaction price, such as variable amounts for incentive or award fees; and performance being better or worse than previously estimated.

-9-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

A significant portion of the Company's contracts recognize revenue on performance obligations using a cost input measure (cost-to-cost), which requires estimates of total costs at completion. In cases when total expected costs exceed total estimated revenues for a performance obligation, the Company recognizes the total estimated loss in the quarter identified. Total estimated losses are inclusive of any unexercised options that are probable of award, only if they increase the amount of the loss.

-9-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Aggregate net changes in estimates on contracts accounted for using the cost-to-cost method of accounting were recognized in operating income as follows:

	Three Months Ended	Three Months Ended	Six Months Ended
	May 3, 2024	May 3, 2024	May 3, 2024
	August 2, 2024	August 4, 2023	August 2, 2024
	(in millions, except per share amounts)	(in millions, except per share amounts)	(in millions, except per share amounts)
Net favorable adjustments			
Net favorable adjustments, after tax			
Net favorable adjustments, after tax			
Net favorable adjustments, after tax			
Net (unfavorable) favorable adjustments			
Net (unfavorable) favorable adjustments, after tax			
Diluted EPS impact			
Diluted EPS impact			
Diluted EPS impact			

Revenues were \$1 million higher for the six months ended August 2, 2024 and \$5 million lower and \$4 million higher for the three and six months ended May 3, 2024 and May 5, 2023 August 4, 2023, respectively, due to net revenue recognized from performance obligations satisfied in prior periods.

Disaggregation of Revenues

The Company's revenues are generated primarily from long-term contracts with the U.S. government including subcontracts with other contractors engaged in work for the U.S. government. The Company disaggregates revenues by customer, contract type and prime versus subcontractor to the federal government for each of its reportable segments.

Disaggregated revenues by customer were as follows:

	Three Months Ended May 3, 2024		Three Months Ended	
	August 2, 2024	August 4, 2023	August 2, 2024	August 4, 2023
	Defense and Intelligence	Defense and Intelligence Civilian Total	Defense and Intelligence Civilian Total	Defense and Intelligence Civilian Total

	(in millions)	(in millions)	(in millions)
Department of Defense			
Intelligence and other federal government agencies			
Commercial, state and local governments and international			
Total			
	Three Months Ended May 5, 2023	Six Months Ended	
	August 2, 2024	August 4, 2023	
	Defense and Intelligence	Defense and Intelligence Civilian Total	Defense and Intelligence Civilian Total
	(in millions)	(in millions)	(in millions)
Department of Defense			
Intelligence and other federal government agencies			
Commercial, state and local governments and international			
Total			

-10-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Disaggregated revenues by contract type were as follows:

	Three Months Ended					
	August 2, 2024			August 4, 2023		
	Defense and Intelligence	Civilian	Total	Defense and Intelligence	Civilian	Total
(in millions)						
Cost reimbursement	\$ 1,085	\$ 20	\$ 1,105	\$ 1,092	\$ 13	\$ 1,105
Time and materials ("T&M")	162	264	426	115	243	358
Firm-fixed price ("FFP")	168	119	287	182	139	321
Total	\$ 1,415	\$ 403	\$ 1,818	\$ 1,389	\$ 395	\$ 1,784

	Three Months Ended May 3, 2024			
	Defense and Intelligence			Civilian
				Total
(in millions)				
Cost reimbursement	\$ 1,134	\$ 21	\$ 1,155	
Time and materials ("T&M")		149	268	417
Firm-fixed price ("FFP")		153	122	275
Total	\$ 1,436	\$ 411	\$ 1,847	

Three Months Ended May 5, 2023

Six Months Ended

	August 2, 2024			August 4, 2023		
	Defense and Intelligence	Defense and Intelligence	Civilian Total	Defense and Intelligence	Civilian Total	Defense and Intelligence
	(in millions)		(in millions)			(in millions)
Cost reimbursement						
Time and materials ("T&M")						
Firm-fixed price ("FFP")						
Total						

Disaggregated revenues by prime versus subcontractor were as follows:

	Three Months Ended May 3, 2024			Three Months Ended		
	Defense and Intelligence	Defense and Intelligence	Civilian Total	Defense and Intelligence	Civilian Total	Defense and Intelligence
	(in millions)		(in millions)			(in millions)
Prime contractor to federal government						
Subcontractor to federal government						
Other						
Total						

	Three Months Ended May 5, 2023			Six Months Ended		
	Defense and Intelligence	Defense and Intelligence	Civilian Total	Defense and Intelligence	Civilian Total	Defense and Intelligence
	(in millions)		(in millions)			(in millions)
Prime contractor to federal government						
Subcontractor to federal government						
Other						
Total						

Contract Balances

Contract balances for the periods presented were as follows:

	Balance Sheet line item	May 3, 2024		February 2, 2024	
		(in millions)			
Billed and billable receivables, net ⁽¹⁾	Receivables, net	\$	567	\$	555
Contract assets - unbillable receivables	Receivables, net		367		359
Contract assets - contract retentions	Other assets		15		14
Contract liabilities - current	Other accrued liabilities		36		53
Contract liabilities - non-current	Other long-term liabilities	\$	1	\$	2

(1) Net of allowance of \$3 million as of May 3, 2024 and February 2, 2024.

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Contract Balances

Contract balances for the periods presented were as follows:

	Balance Sheet line item		August 2, 2024	February 2, 2024
(in millions)				
Billed and billable receivables, net ⁽¹⁾	Receivables, net	\$	574	\$ 555
Contract assets - unbillable receivables	Receivables, net		372	359
Contract assets - contract retentions	Other assets		15	14
Contract liabilities - current	Other accrued liabilities		23	53
Contract liabilities - non-current	Other long-term liabilities	\$	1	\$ 2

(1) Net of allowance of \$3 million as of August 2, 2024 and February 2, 2024.

During the three and six months ended **May 3, 2024 and May 5, 2023** **August 2, 2024**, the Company recognized revenues of **\$20** **\$10** million and **\$21** **\$30** million, respectively, relating to amounts that were included in the opening balance of contract liabilities as of February 2, 2024. During the three and **February 3, 2023** six months ended August 4, 2023, respectively, the Company recognized revenues of \$12 million and \$33 million, respectively, relating to amounts that were included in the opening balance of contract liabilities as of February 3, 2023.

Remaining Performance Obligations

Remaining performance obligations ("RPO") represent the transaction price of exercised contracts (both funded and unfunded) less inception to date revenue recognized. RPO does not include unexercised option periods and future task orders expected to be awarded under IDIQ contracts. As of **May 3, 2024** **August 2, 2024**, the Company had approximately \$5.4 billion of **remaining performance obligations** **RPO**. The Company expects to recognize revenue on approximately **81%** **79%** of the **remaining performance obligations** **RPO** over the next 12 months and approximately **91%** **90%** over the next 24 months, with the remaining recognized thereafter.

Note 4—Divestitures:

FSA Amendment

On February 4, 2023, the Company sold 0.1% of its 50.1% majority ownership interest in Forfeiture Support Associates J.V. ("FSA") to its sole joint venture partner for a nominal amount. In conjunction with the sale, the Company remeasured its retained investment in FSA to a fair value of \$14 million. As a result of the sale and amendment to the joint venture operating agreement of FSA, the Company no longer controls the joint venture and will account for its retained interest as an equity method investment as of the date of the transaction.

The equity method investment is included within "Other assets" on the condensed consolidated balance sheets. The remeasurement resulted in a gain of \$7 million which is included within "(Gain) loss on divestitures, net of transaction costs" on the condensed consolidated statements of income and is reflected within "(Gain) loss on divestitures" on the condensed consolidated statements of cash flows. **flows for the six months ended August 4, 2023**. The Company estimated the fair value of its retained investment in FSA based on Level 3 inputs of the fair value hierarchy. The Company used the income approach which involves the use of estimates and assumptions, including revenue growth rates, projected operating margins, discount rates and terminal growth rates.

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Sale of Logistics and Supply Chain Management Business

On **March 23, 2023** **May 6, 2023**, the Company executed a definitive agreement to sell closed the sale of its logistics and supply chain management business ("Supply Chain Business") to ASRC Federal Holding Company, LLC ("ASRC Federal"), for \$356 million in cash, including \$355 million received at closing and a subsidiary preliminary post-closing adjustment for working capital. The Company recognized the cash as "Proceeds from divestitures" on the condensed consolidated statements of Arctic Slope Regional Corporation, for \$350 cash flows. The sale enables the Company to focus its resources on long-term strategic growth areas. During the second quarter of fiscal 2024, the Company recorded a preliminary pre-tax gain of \$233 million, net of \$7 million of pre-tax cash proceeds, subject to certain adjustments for working capital, transaction costs, which is included within "(Gain) loss on divestitures, net of transaction costs" on the condensed consolidated statements of income.

The disposition did not represent a strategic shift in operations that would have a material effect on the Company's operations and financial results, and accordingly has not been presented as discontinued operations.

During the first quarter **The major classes of fiscal 2024**, the Company received a refundable cash deposit of \$355 million which represented the expected proceeds due upon closing of the transaction with ASRC Federal including preliminary adjustments for working capital. The Company recognized the cash assets and liabilities divested were as "Proceeds from assets held for sale" on the condensed consolidated statements of cash flows. follows:

	(in millions)
Assets:	
Receivables, net	\$ 46
Inventories, net	72
Prepaid expenses	1
Goodwill	60
Operating lease right of use assets	2
Total assets divested	\$ 181
Liabilities:	
Accounts payable	\$ 62
Accrued payroll and employee benefits	1
Other accrued liabilities	1
Operating lease liabilities	1
Total liabilities divested	\$ 65

In connection with the sale, the Company and ASRC Federal entered into certain transition services agreements pursuant to which the Company provided certain services to ASRC Federal through the first quarter of fiscal 2025 on a cost reimbursable basis. The transition services included certain IT, finance and other services necessary to support the transition of the sale.

-12-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Note 5—Goodwill and Intangible Assets:

Goodwill

The following table presents the carrying value of goodwill by reportable segment:

		May 3, 2024
		May 3, 2024
		May 3, 2024
		August 2, 2024
		August 2, 2024
		August 2, 2024
		(in millions)
		(in millions)
		(in millions)
Defense and Intelligence		
Civilian		
Civilian		
Civilian		
Total		
Total		
Total		

Goodwill is not amortized, but rather tested for potential impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The goodwill impairment test is performed at

-13-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

the reporting unit level. As a result of the internal reorganization on February 3, 2024, the Company reallocated its goodwill to its five new goodwill reporting units.

The Company performed a goodwill impairment test immediately before and after the reorganization, both of which resulted in no impairment. For the goodwill impairment test immediately after the reorganization, the Company performed a quantitative assessment of its goodwill as of February 3, 2024 for its five new goodwill reporting units. The Company estimated the fair value of each reporting unit using a 50:50 weighting of fair values derived from an income approach and market approach.

Under the income approach, the Company estimated the fair value of its reporting units using a multi-year discounted cash flow model involving assumptions about projected future revenue growth, operating margins, income tax rates, capital expenditures, discount rate, and terminal value.

Under the market approach, the Company estimated the fair value of its reporting units based on multiples of earnings derived from observable market data of comparable public companies.

Intangible Assets

Intangible assets, all of which were finite-lived, consisted of the following:

	May 3, 2024			February 2, 2024			August 2, 2024			February 2, 2024					
	Gross	Gross	Net	Gross	Gross	Net	Gross	Gross	Net	Gross	Gross	Net			
	carrying	carrying	Accumulated	carrying	carrying	amortization	carrying	carrying	value	carrying	Accumulated	carrying	carrying	value	value
(in millions)															
Customer relationships															
Developed technology															
Trade name															
Total intangible assets															

Amortization expense related to intangible assets was \$29 million and \$58 million for the three and six months ended May 3, 2024 August 2, 2024 and May 5, 2023 August 4, 2023, respectively. There were no intangible asset impairment losses during the periods presented.

-13-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

As of May 3, 2024 August 2, 2024, the estimated future annual amortization expense related to intangible assets is as follows:

Fiscal Year	Fiscal Year	(in millions)	Fiscal Year	(in millions)
Remainder of 2025				
2026				
2027				
2028				
2029				
Thereafter				
Total				

Actual amortization expense in future periods could differ from these estimates as a result of future acquisitions, divestitures, impairments, and other factors.

Note 6—Income Taxes:

The Company's effective income tax rate was 19.0% 19.6% and 20.0% 19.3% for the three and six months ended May 3, 2024 August 2, 2024, respectively, and May 5, 2023 26.4% and 24.7% for the three and six months ended August 4, 2023, respectively. The Company's effective tax rate primarily differs from the statutory tax rate due to the deduction for foreign derived intangible income, research and development tax credits, and stock-based compensation windfalls.

-14-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

The Company's effective tax rate for the three and six months ended **May 3, 2024**, is lower **August 2, 2024** decreased compared to the effective tax rate from the same period periods in the prior year primarily due to higher tax benefits the non-recurrence of a gain from the deduction for foreign-derived intangible income, disposition of the Supply Chain Business and the associated non-deductible goodwill.

Note 7—Debt Obligations:

The Company's long-term debt as of the dates presented was as follows:

	May 3, 2024				February 2, 2024	August 2, 2024				February 2, 2024			
	Stated interest rate	Effective interest rate	Principal	Unamortized debt issuance costs Net	Unamortized debt issuance costs Net	Stated interest rate	Effective interest rate	Principal	Unamortized debt issuance costs Net	Unamortized debt issuance costs Net	Principal	Unamortized debt issuance costs Net	
					(dollars in millions)								
Term Loan A Facility due June 2027													
Term Loan B Facility due October 2025													
Term Loan B2 Facility due March 2027													
Term Loan B3 Facility due February 2031													
Senior Notes due April 2028													
Total long-term debt													
Revolving Credit Facility due June 2027													
Total debt													
Less current portion													
Total long-term debt, net of current portion													
Total debt, net of current portion													

As of **May 3, 2024** **August 2, 2024**, the Company had a \$2.7 billion secured credit facility (the Credit Facility) consisting of a Term Loan A Facility due June 2027, a Term Loan B3 Facility due February 2031 (together, the "Term Loan Facilities"), and a \$1.0 billion Revolving Credit Facility due June 2027 (the "Revolving Credit Facility").

On February 8, 2024, the Company executed the Sixth Amendment to the Third Amended and Restated Credit Agreement ("Sixth Amendment"), which established a \$510 million senior secured term loan credit facility ("Term Loan B3 Facility due February 2031"). The entire Term Loan B3 Facility due February 2031 was immediately borrowed by the Company and the proceeds were used to pay in full the outstanding principal balances under the Term Loan B Facility due October 2025 and Term Loan B2 Facility due March 2027. The Tranche B3 Facility is subject to the same covenants and events of default as the Company's existing Term Loan Facilities.

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Borrowings under the Term Loan B3 Facility due February 2031 amortize quarterly beginning on July 31, 2024 at 0.25% of the original borrowed amount with the remaining unamortized balance due in full upon its maturity on February 8, 2031. Borrowings will bear interest based on the Term Secured Overnight Financing Rate ("Term SOFR") or a base rate, plus an applicable margin of 1.875% for Term SOFR loans and 0.875% for base rate loans. In the event any portion of the Term Loan B3 Facility due February 2031 is repaid prior to August 8, 2024 as a result of a repricing event, the Company will be required to repay a 1.00% fee of the amount repaid. After this initial six month period, the Term Loan B3 Facility due February 2031 may be prepaid at any time without penalty and is subject to the same mandatory prepayments, including from excess cash flow, as the Company's existing term loans under the Credit Facility.

During the **three** **six** months ended **May 3, 2024** **August 2, 2024**, the Company incurred \$5 million of debt issuance costs associated with the Sixth Amendment, of which \$3 million was recognized in interest expense and the remaining \$2 million deferred and amortized to interest expense through the maturity date of the facility utilizing the effective interest rate method.

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

During the **three** **and six** months ended **May 3, 2024** **August 2, 2024**, the Company made **a** **scheduled principal payment** **payments** of **\$15** **\$16** million and **\$31** million, respectively, on the Term Loan A Facility due June **2027**. **2027** and made a scheduled principal payment of **\$1** million on the Term Loan B3 Facility due February **2031**.

During the **three** **and six** months ended **May 3, 2024** **August 2, 2024**, the Company borrowed \$380 million and \$570 million, respectively, and repaid **\$190** **\$280** million and **\$470** million, respectively, under the Revolving Credit Facility. **There** **As** **of** **August 2, 2024**, the outstanding principal under the Revolving Credit Facility was **no** classified as current portion of debt on the condensed consolidated balance **outstanding** **sheets**. Subsequent to quarter end, the Company repaid \$50 million on the Revolving Credit Facility as of May 3, 2024. Facility. Commitment fees for undrawn amounts under the Revolving Credit Facility range from 0.125% to 0.25% per annum based on the Company's leverage ratio.

As of **May 3, 2024** **August 2, 2024**, the Company was in compliance with the covenants under its Credit Facility.

As of **May 3, 2024** **August 2, 2024** and February 2, 2024, the carrying value of the Company's outstanding debt obligations approximated its fair value. The fair value of **long-term** debt is calculated using Level 2 inputs, based on interest rates available for debt with terms and maturities similar to the Company's Term Loan Facilities and Senior Notes.

Maturities of **long-term** debt as of **May 3, 2024** **August 2, 2024** are:

Fiscal Year	Fiscal Year	Total Fiscal Year	Total
(in millions)			
Remainder of 2025			
2026			
2027			
2028			

2029

Thereafter

Total principal payments

-15-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Note 8—Derivative Instruments Designated as Cash Flow Hedges:

The Company's derivative instruments designated as cash flow hedges consist of:

								Fair Value of Asset ⁽¹⁾ at
	Notional Amount	Pay Fixed	Receive	Variable	Settlement and	May 3,	2024	
	at May 3, 2024	Rate	Rate	Rate	Termination	2024	February 2, 2024	
(in millions)							(in millions)	
Interest rate swaps	\$ 685	2.96 %	1-month Term SOFR	Monthly through October	31, 2025	\$ 19	\$ 15	

								Fair Value of Asset ⁽¹⁾ at
	Notional Amount	Pay Fixed	Receive	Variable	Settlement and	August 2,	2024	
	at August 2, 2024	Rate	Rate	Rate	Termination	2024	February 2, 2024	
(in millions)							(in millions)	
Interest rate swaps	\$ 685	2.96 %	1-month Term SOFR	Monthly through October	31, 2025	\$ 9	\$ 15	

(1) The fair value of the fixed interest rate swap asset is included in "Other assets" on the condensed consolidated balance sheets.

The Company is party to fixed interest rate swap instruments that are designated and accounted for as cash flow hedges to manage risks associated with interest rate fluctuations on a portion of the Company's floating rate debt within the Credit Facility. The counterparties to all swap agreements are financial institutions.

See Note 9—Changes in Accumulated Other Comprehensive Income (Loss) by Component for the unrealized change in fair values on cash flow hedges recognized in other comprehensive income (loss) and the amounts reclassified from accumulated other comprehensive income (loss) into earnings for the current and comparative periods presented. The Company estimates that it will reclassify \$14 million \$8 million of unrealized gains from accumulated other comprehensive income into earnings in the twelve months following May 3, 2024 August 2, 2024.

-16-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Note 9—Changes in Accumulated Other Comprehensive Income (Loss) by Component:

The following table presents the changes in accumulated other comprehensive income (loss) attributable to the Company's fixed interest rate swap cash flow hedges that are discussed in Note 8—Derivative Instruments Designated as Cash Flow Hedges and the Company's defined benefit plans.

				Unrealized Gains (Losses) on Fixed
		Unrealized Gains (Losses) on Fixed Interest Rate Swap Cash Flow Hedges ⁽¹⁾	Defined Benefit Obligation Adjustment	Total
		(in millions)		
Three months ended August 2, 2024				
Balance at May 3, 2024	\$	14	\$ 5	\$ 19
Other comprehensive loss before reclassifications		(6)	—	(6)
Amounts reclassified from accumulated other comprehensive income		(4)	—	(4)
Income tax impact		2	—	2
Net other comprehensive loss		(8)	—	(8)
Balance at August 2, 2024	\$	6	\$ 5	\$ 11
Three months ended August 4, 2023				
Balance at May 5, 2023	\$	12	\$ 4	\$ 16
Other comprehensive income before reclassifications		15	—	15
Amounts reclassified from accumulated other comprehensive income		(6)	—	(6)
Income tax impact		(2)	—	(2)
Net other comprehensive income		7	—	7
Balance at August 4, 2023	\$	19	\$ 4	\$ 23
Six months ended August 2, 2024				
Balance at February 2, 2024	\$	11	\$ 5	\$ 16
Other comprehensive income before reclassifications		82	—	82
Amounts reclassified from accumulated other comprehensive income		(4)(8)	—	(4)(8)
Income tax impact		(1)1	—	(1)1
Net other comprehensive income loss		3(5)	—	3(5)
Balance at May 3, 2024 August 2, 2024	\$	14	\$ 5	\$ 19 11
Three Six months ended May 5, 2023 August 4, 2023				
Balance at February 3, 2023	\$	18	\$ 4	\$ 22
Other comprehensive loss income before reclassifications		(2)13	—	(2)13
Amounts reclassified from accumulated other comprehensive loss income		(6)(12)	—	(6)(12)
Income tax impact		2—	—	2—
Net other comprehensive loss income		(6)1	—	(6)1
Balance at May 5, 2023 August 4, 2023	\$	12	\$ 4	\$ 16 23

(1) The amount reclassified from accumulated other comprehensive income (loss) is included in "Interest expense, net."

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Note 10—Sales of Receivables:

The Company has a Master Accounts Receivable Purchase Agreement ("MARPA Facility") with MUFG Bank, Ltd. (the "Purchaser") for the sale of up to a maximum amount of \$300 million of certain designated eligible receivables with the U.S. government.

During the three and six months ended May 3, 2024 and May 5, 2023 August 2, 2024, the Company incurred purchase discount fees of \$3 million \$4 million and \$7 million, which respectively. During the three and six months ended August 4, 2023, the Company incurred purchase discount fees of \$2 million and \$5 million, respectively. The purchase discount fees are presented in "Other (income) expense, net" on the condensed consolidated statements of income and are reflected as cash flows from operating activities on the condensed consolidated statements of cash flows.

MARPA Facility activity consisted of the following:

	Three Months Ended	
	May 3, 2024	May 5, 2023
	Six Months Ended	
Beginning balance		
Sale of receivables		
Cash collections		
Outstanding balance sold to Purchaser ⁽¹⁾		
Cash collected, not remitted to Purchaser ⁽²⁾		
Remaining sold receivables		

(in millions)

Beginning balance

Sale of receivables

Cash collections

Outstanding balance sold to Purchaser⁽¹⁾

Cash collected, not remitted to Purchaser⁽²⁾

Remaining sold receivables

- (1) For the three six months ended May 3, 2024 August 2, 2024, the Company recorded a net increase decrease of \$79 \$30 million to cash flows from operating activities from sold receivables. For the three six months ended May 5, 2023 August 4, 2023, there was no net impact to cash flows from operating activities from sold receivables.
- (2) Primarily represents the cash collected on behalf of but not yet remitted to the Purchaser as of May 3, 2024 August 2, 2024 and May 5, 2023 August 4, 2023. This balance is included in "Accounts payable" on the condensed consolidated balance sheets.

Note 11—Business Segments Information:

Effective February 3, 2024, the first day of fiscal 2025, the Company completed a business reorganization which replaced its previous two customer facing operating sectors with five customer facing business groups supported by the enterprise organizations, including the Innovation Factory. The five business groups represent the Company's operating segments and have been aggregated into two reportable segments (Defense and Intelligence, and Civilian) given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. The Company defines its operating segments based on the way the CODM, currently the Company's CEO, manages the operations for the purpose of allocating resources and assessing performance.

The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the defense and intelligence departments and agencies of the United States Government.

The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy.

The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives, including IT modernization, digital engineering, AI, mission systems support, training and simulation, and ground vehicles support. These services include end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment and security of the customers' entire IT infrastructure.

-17--18-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate.

The segment information for the periods presented was as follows:

Revenues:

Defense and Intelligence

Defense and Intelligence

Defense and Intelligence

Civilian

Civilian

Civilian

Total revenues

Total revenues

Total revenues

Operating income (loss):

Operating income (loss):

Operating income (loss):

Defense and Intelligence

Defense and Intelligence
Defense and Intelligence
Civilian
Civilian
Civilian
Corporate
Corporate
Corporate
<hr/>
Total operating income
<hr/>
Total operating income
<hr/>
Total operating income
<hr/>
Total operating income (loss)

The income statement performance measures regularly provided to the CODM are "Revenues" and "Operating income." As a result, "Interest expense, net," "Other (income) expense, net" and "Provision for income taxes" as reported in the condensed consolidated statements of income are not allocated to the Company's segments.

Asset information by segment is not a key measure of performance used by the CODM.

Note 12—Legal Proceedings and Other Commitments and Contingencies:

Legal Proceedings

The Company is involved in various claims and lawsuits arising in the normal conduct of its business, none of which the Company's management believes, based on current information, is expected to have a material adverse effect on the Company's financial position, results of operations or cash flows.

In April 2022 and October 2023, the Company received Federal Grand Jury Subpoenas in connection with a criminal investigation being conducted by the U.S. Department of Justice, Antitrust Division ("DOJ"). As required by the subpoenas, the Company has provided the DOJ with a broad range of documents related to the investigation, and the Company's collection and production process remains ongoing. The Company is fully cooperating with the investigation. At this time, it is not possible to determine whether the Company will incur, or to reasonably estimate the amount of, any fines, penalties or further liabilities in connection with the investigation pursuant to which the subpoenas were issued.

AAV Termination for Convenience

On August 27, 2018, the Company received a stop-work order from the United States Marine Corps on the Assault Amphibious Vehicle ("AAV") contract and on October 3, 2018 the program was terminated for convenience by the customer. The Company is continuing to negotiate with the Marine Corps to recover costs associated with the termination.

-18- **-19-**

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Government Investigations, Audits and Reviews

The Company is routinely subject to investigations and reviews relating to compliance with various laws and regulations with respect, in particular, to its role as a contractor to federal, state and local government customers and in connection with performing services in countries outside of the United States. U.S. government agencies, including the Defense Contract Audit Agency ("DCAA"), the Defense Contract Management Agency and others, routinely audit and review a contractor's performance on government contracts, indirect rates and pricing

practices, and compliance with applicable contracting and procurement laws, regulations and standards. They also review the adequacy of the contractor's compliance with government standards for its business systems. Adverse findings in these investigations, audits, or reviews can lead to criminal, civil or administrative proceedings, and the Company could face disallowance of previously billed costs, penalties, fines, compensatory damages and suspension or debarment from doing business with governmental agencies. Due to the Company's reliance on government contracts, adverse findings could also have a material impact on the Company's business, including its financial position, results of operations and cash flows.

The indirect cost audits by the DCAA of the Company's business remain open for certain prior years and the current year. Although the Company has recorded contract revenues based on an estimate of costs that the Company believes will be approved on final audit, the Company does not know the outcome of any ongoing or future audits. If future completed audit adjustments exceed the Company's reserves for potential adjustments, the Company's profitability could be materially adversely affected.

As of **May 3, 2024** **August 2, 2024**, the Company believes it has adequately reserved for estimated net amounts to be refunded to customers for potential adjustments for indirect cost audits and compliance with U.S. government Cost Accounting Standards.

Letters of Credit and Surety Bonds

The Company has outstanding obligations relating to letters of credit of **\$10 million** **\$9 million** as of **May 3, 2024** **August 2, 2024**, principally related to guarantees on insurance policies. The Company also has outstanding obligations relating to surety bonds of \$19 million, principally related to performance and payment bonds on the Company's contracts.

Note 13—Subsequent Events

Sale of Equity Method Investment

On August 30, 2024, Morpheus Data, one of the Company's unconsolidated venture investments, completed a transaction to sell all its outstanding equity to Hewlett Packard Enterprise (NYSE: HPE). The carrying value of the Company's investment was \$5 million as of August 2, 2024 and is recorded within "Other assets" on the condensed consolidated balance sheets. The transaction is not expected to result in a loss for the Company.

Quarterly Dividend Declared

On August 29, 2024, the Company's Board of Directors declared a quarterly dividend of \$0.37 per share of the Company's common stock payable on October 25, 2024 to stockholders of record on October 11, 2024.

-19-

-20-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations and quantitative and qualitative disclosures about market risk should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes. It contains forward-looking statements (which may be identified by words such as those described in "Risk Factors—Forward-Looking Statement Risks" in Part I of the most recently filed Annual Report on Form 10-K), including statements regarding our intent, belief, or current expectations with respect to, among other things, trends affecting our financial condition or results of operations (including our financial targets discussed below under "Management of Operating Performance and Reporting" and "Liquidity and Capital Resources"); backlog; our industry; government budgets and spending; market opportunities; the impact of competition; and the impact of acquisitions and divestitures. Such statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those in the forward-looking statements as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these differences include those discussed below, in "Risk Factors" in Part II of this report and in Part I of the most recently filed Annual Report on Form 10-K. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which

speak only as of the date hereof. We do not undertake any obligation to update these factors or to publicly announce the results of any changes to our forward-looking statements due to future results or developments.

We use the terms "SAIC," the "Company," "we," "us" and "our" to refer to Science Applications International Corporation and its consolidated subsidiaries.

The Company utilizes a 52/53 week fiscal year, ending on the Friday closest to January 31, with fiscal quarters typically consisting of 13 weeks. Fiscal 2025 began on February 3, 2024 and ends on January 31, 2025, while fiscal 2024 began on February 4, 2023 and ended on February 2, 2024.

Business Overview

We are a leading technology integrator providing full life cycle services and solutions in the technical, engineering and enterprise information technology ("IT") markets. We developed our brand by addressing our customers' mission critical needs and solving their most complex problems for over 50 years. As one of the largest pure-play technology service providers to the U.S. government, we serve markets of significant scale and opportunity. Our primary customers are the departments and agencies of the U.S. government. We serve our customers through approximately 1,800 active contracts and task orders and employ approximately 24,000 individuals who are led by an experienced executive team of proven industry leaders. Our long history of serving the U.S. government has afforded us the ability to develop strong and longstanding relationships with some of the largest customers in the markets we serve. Substantially all of our revenues and tangible long-lived assets are generated and located in the United States.

Effective February 3, 2024, the first day of fiscal 2025, we completed a business reorganization which replaced our previous two operating sectors with five customer facing business groups supported by the enterprise organizations, including the Innovation Factory. The five business groups represent our operating segments and have been aggregated into two reportable segments (Defense and Intelligence, and Civilian) given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve.

The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the defense and intelligence departments and agencies of the United States Government.

The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy.

The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives, including IT modernization, digital engineering, artificial intelligence ("AI"), mission systems support and advisory, training and simulation, and ground vehicles support. These services include end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment and security of the customers' entire IT infrastructure.

-20-**21**

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Our Innovation Factory supports the operating segments by developing superior enterprise-class solutions which are delivered to the our customers as stand-alone solutions or integrated with and aligned to product offerings through the operations of the business to meet complex customer needs and accelerate digital transformation. The Innovation Factory includes designated teams focused on AI, application development, network services, platforms and cloud, and cyber. **cybersecurity**. It uses a highly automated, cloud-hosted tool set to rapidly build, test and deploy solutions quickly and works with customers to enhance solutions going forward.

Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate. See Note 11—Business Segments Information to the condensed consolidated financial statements contained within this report for additional information.

Economic Opportunities, Challenges, and Risks

During the three and six months ended **May 3, 2024** August 2, 2024, we generated 98% of our revenues from contracts with the U.S. government, including subcontracts on which we perform. Our business performance is affected by the overall level of U.S. government spending and the alignment of our offerings and capabilities with the budget priorities of the U.S. government. Appropriations measures passed in December 2022 provided full funding for the federal government through the end of government fiscal year ("GFY") 2023. In March 2024, the President signed appropriation measures that provide funding for GFY 2024 for all of the U.S. government and submitted the GFY 2025 budget request which adheres to the Fiscal Responsibility Act of 2023. The GFY 2025 budget includes 1% growth for defense budgets and an overall 1% growth for non-defense budgets. If Congress is not able to pass the GFY 2025 funding measures by the end of September 2024, it could result in the U.S. government operating on a continuing resolution or could potentially lead to a partial or full government shutdown.

In January 2023, the Federal debt ceiling was reached and the U.S. Department of the Treasury was operating under "extraordinary measures." In June 2023, the President signed the Fiscal Responsibility Act of 2023 which suspends the Federal debt ceiling until January 1, 2025, postponing the threat of a federal government default. If a new debt ceiling agreement is not reached by January 2025, the U.S. Department of the Treasury will return to operating under "extraordinary measures."

Adverse changes in fiscal and economic conditions could materially impact our business. Some changes that could have an adverse impact on our business include adverse regulations, the implementation of future spending reductions (including sequestration), delayed passage of appropriations bills resulting in temporary or full-year continuing resolutions, extreme inflationary increases adversely impacting fixed price contracts, and potential government shutdowns.

Spending packages, including the infrastructure bill, Inflation Reduction Act, and CHIPS and Science Act, as well as future potential spending packages, may provide additional opportunity in areas of SAIC focus such as digital modernization, cyber, microelectronics support, and climate resiliency.

The U.S. government has increasingly relied on contracts that are subject to a competitive bidding process (including indefinite delivery, indefinite quantity ("IDIQ"), U.S. General Services Administration ("GSA") schedules, and other multi-award contracts), which has resulted in greater competition and increased pricing pressure. Additionally, the U.S. government has put renewed emphasis on increasing the number of small business prime set-aside contracts that further reduce the addressable market in some areas.

Despite the budget and competitive pressures affecting the industry, we believe we are well-positioned to protect and expand existing customer relationships and benefit from opportunities that we have not previously pursued. Our scale, size, and prime contractor leadership position are expected to help differentiate us from our competitors, especially on large contract opportunities. We believe our long-term, trusted customer relationships and deep technical expertise provide us with the sophistication to handle highly complex, mission-critical contracts. Our value proposition is found in the proven ability to serve as a trusted adviser to our customers. In doing so, we leverage our expertise and scale to help them execute their mission.

We succeed as a business based on the solutions we deliver, our past performance, and our ability to compete on price. Our solutions are inspired through innovation based on adoption of best practices and technology integration of the best capabilities available. Our Innovation Factory develops superior enterprise-class solutions which are delivered to our customers as stand-alone solutions or integrated with and aligned to our product offerings to meet complex customer needs and accelerate the digital transformation. Our past performance was achieved by employees dedicated to supporting our customers' most challenging missions. Our current cost structure and ongoing efforts to reduce costs by strategic sourcing and developing repeatable offerings sold "as a service" and as

-21- -22-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

ongoing efforts to reduce costs by strategic sourcing and developing repeatable offerings sold "as a service" and as managed services in a more commercial business model are expected to allow us to compete effectively on price in an evolving environment. Our ability to be competitive in the future will continue to be driven by our reputation for successful program execution, competitive cost structure, development of new pricing and business models, and efficiencies in assigning the right people, at the right time, in support of our contracts.

Management of Operating Performance and Reporting

Our business and program management process is directed by professionals focused on serving our customers by providing high quality services in achieving program requirements. These professionals carefully monitor contract margin performance by constantly evaluating contract risks and opportunities. Throughout each contract's life cycle, program managers review performance and update contract performance estimates to reflect their understanding of the best information available.

We evaluate our results of operations by considering the drivers causing changes in revenues, operating income and operating cash flows. Given that revenues fluctuate on our contract portfolio over time due to contract awards and completions, changes in customer requirements, and increases or decreases in ordering volume of materials, we evaluate significant trends and fluctuations resulting from these factors. Whether performed by our employees or by our subcontractors, we primarily provide services and, as a result, our cost of revenues are predominantly variable. We also analyze our cost mix (labor, subcontractor and materials) in order to understand operating margin because programs with a higher proportion of SAIC labor are generally more profitable. Changes in cost of revenues as a percentage of revenues other than from revenue volume or cost mix are normally driven by fluctuations in shared or corporate costs, or cumulative revenue adjustments due to changes in estimates.

Changes in operating cash flows are described with regard to changes in cash generated through the provision of services, significant drivers of fluctuations in assets or liabilities and the impacts of changes in timing of cash receipts or disbursements.

Condensed Consolidated Results of Operations

The primary financial performance measures we use to manage our business and monitor results of operations are revenues, operating income, and cash flows from operating activities. The following table summarizes our condensed consolidated results of operations:

	Three Months Ended		Six Months Ended		
	August 2, 2024, change	August 4, 2023	August 2, 2024, change	August 4, 2023	
	(dollars in millions)		(dollars in millions)		
Revenues					
Cost of revenues					
Cost of revenues					
Cost of revenues					
As a percentage of revenues					
As a percentage of revenues					
As a percentage of revenues					
Selling, general and administrative expenses					
Selling, general and administrative expenses					
Selling, general and administrative expenses					
(Gain) loss on divestitures, net of transaction costs					
(Gain) loss on divestitures, net of transaction costs					
(Gain) loss on divestitures, net of transaction costs					
Other operating (income) expense					
Other operating (income) expense					
Other operating (income) expense					
Operating income					

Operating income				
Operating income				
As a percentage of revenues	As a percentage of revenues	7.4 %	20.3 %	7.2 %
As a percentage of revenues				13.6 %
As a percentage of revenues				
Provision for income taxes				
Provision for income taxes				
Provision for income taxes				
Net income				
Net income				
Net income				
Net cash provided by operating activities				
Net cash provided by operating activities				
Net cash provided by operating activities				

Revenues. Revenues decreased \$181 million increased \$34 million for the three months ended May 3, 2024 August 2, 2024 as compared to the same period in the prior year primarily due to ramp up in volume on existing and new contracts, partially offset by contract completions.

-23-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Revenues decreased \$147 million for the six months ended August 2, 2024 as compared to the same period in the prior year primarily due to the sale of the Supply Chain Business (\$188 million) in the prior year (see Note 4—Divestitures to the condensed consolidated financial statements), and contract completions. This was partially offset by ramp up in volume on existing and new contracts. Adjusting contracts. Adjusting for the impact of the divestiture, revenues grew 0.4% 1.1%.

-22-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Operating Income. Operating income as a percentage of revenues for the three months ended May 3, 2024 August 2, 2024 decreased from the comparable prior year period primarily due to the gain on the sale of the Supply Chain Business (\$234 million) in the prior year period, and contract completions, partially offset by ramp up in volume on existing and new contracts.

Operating income as a percentage of revenues for the six months ended August 2, 2024 decreased from the comparable prior year period primarily due to the gain on the sale of the Supply Chain Business (\$233 million) in the prior year, a gain recognized from the deconsolidation of FSA in the prior year period, (\$7 million), and contract completions, partially offset by ramp up in volume on existing and new contracts.

Income Taxes. Our effective income tax rate was 19.0% 19.6% and 20.0% 19.3% for the three and six months ended May 3, 2024 August 2, 2024, respectively, and May 5, 2023 26.4% and 24.7% for the three and six months ended August 4, 2023, respectively. Our effective tax rate differs from the statutory tax rate primarily due to the deduction for foreign derived intangible income, research and development tax credits, and stock-based compensation windfalls.

Our effective tax rate for the three and six months ended May 3, 2024, is lower August 2, 2024 decreased compared to the effective tax rate same periods in the previous year due to the non-recurrence of a gain from the same period in disposition of the prior year primarily due to higher tax benefits from Supply Chain Business and the deduction for foreign-derived intangible income associated non-deductible goodwill.

Beginning in fiscal 2023, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenditures immediately in the year incurred and requires taxpayers to amortize such expenditures over five years for tax purposes. While the impact to income taxes payable was most significant in fiscal 2023, this impact will decrease over the five-year amortization period and is anticipated to be immaterial in year six. The actual impact will depend on the amount of research and development costs incurred by us, whether Congress modifies or repeals this provision and whether new guidance and interpretive rules are issued by the U.S. Treasury, among other factors.

In December 2021, the Organisation for Economic Co-operation and Development (OECD) enacted model rules for a new 15% global minimum tax framework ("Pillar Two") which became effective in certain jurisdictions beginning in fiscal 2024. We do not anticipate Pillar Two to have a significant impact on our effective tax rate or our consolidated results of operations, financial position, and cash flows.

Cash Flows Provided by Operating Activities. Cash flows provided by operating activities increased \$16 million for the three months ended May 3, 2024 as compared to the prior year primarily due to the higher cash provided by the Master Accounts Receivable Purchase Agreement ("MARPA Facility") in the current year (see Note 10—Sales of Receivables to the condensed consolidated financial statements contained within this report for additional information), partially offset by higher incentive-based compensation payments in the current year and other changes in working capital.

Segment and Corporate Results

The primary financial performance measures we use to manage our reportable segments and monitor results of operations are revenues and operating income. The following tables summarize our results of operations by reportable segment:

Defense and Intelligence	Defense and Intelligence	Three Months Ended		Six Months Ended			
Defense and Intelligence	Defense and Intelligence	August 2, 2024	Percent change	August 4, 2023	August 2, 2024	Percent change	August 4, 2023
Defense and Intelligence		(dollars in millions)				(dollars in millions)	
Revenues							
Operating income							
Operating income							
Operating income							
As a percentage of revenues	As a percentage of revenues	7.6 %		7.6 %	7.5 %		7.7 %
As a percentage of revenues							
As a percentage of revenues							

Revenues: Revenues decreased \$161 million increased \$26 million for the three months ended May 3, 2024 August 2, 2024 as compared to the same period in the prior year primarily due to ramp up in volume on existing and new contracts, partially offset by contract completions.

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Revenues decreased \$135 million for the six months ended August 2, 2024 as compared to the same period in the prior year primarily due to the sale of the Supply Chain Business (\$188 million) in the prior year, and contract completions. This was partially offset by ramp up in volume on existing and new contracts. Adjusting for the impact of the divestiture, revenues grew 1.9%.

Operating Income. Income: Operating income as a percentage of revenues for the three months ended May 3, 2024 August 2, 2024 was comparable to the prior year period, primarily due to ramp up in volume on existing and new contracts, offset by contract completions.

Operating income as a percentage of revenues for the six months ended August 2, 2024 decreased from the comparable prior year period primarily due to contract completions and the sale of the Supply Chain Business in the prior year. partially offset by ramp up in volume on existing and new contracts.

-23-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Civilian	Civilian	Three Months Ended		Six Months Ended			
Civilian	Civilian	August 2, 2024	Percent change	August 4, 2023	August 2, 2024	Percent change	August 4, 2023
(dollars in millions)						(dollars in millions)	
Revenues							
Operating income							
Operating income							
Operating income							
As a percentage of revenues		As a percentage of revenues		8.4 %	10.9 %		8.4 %
As a percentage of revenues							
As a percentage of revenues							

Revenues: Revenues decreased \$20 million increased \$8 million for the three months ended May 3, 2024 August 2, 2024 as compared to the same period in the prior year primarily due to ramp up in volume on existing contracts.

Revenues decreased \$12 million for the six months ended August 2, 2024 as compared to the same period in the prior year primarily due to reduced volume on existing contracts, partially offset by new contracts.

Operating Income. Income: Operating income as a percentage of revenues for the three months ended May 3, 2024 August 2, 2024 decreased from the comparable prior year period partially due to timing and volume mix.

Operating income as a percentage of revenues for the six months ended August 2, 2024 decreased from the comparable prior year primarily due to reduced volume. volume on existing contracts.

Corporate
Corporate
Corporate

Corporate Three Months Ended Six Months Ended

	August 2, 2024	Percent change	August 4, 2023	August 2, 2024	Percent change	August 4, 2023
(dollars in millions)						
(dollars in millions)						

Operating loss

Operating (loss) income

Operating Loss. (Loss) Income: Operating loss increased \$1 million \$220 million for the three months ended May 3, 2024 August 2, 2024 as compared to the same period in the prior prior year primarily due to the gain recognized from the deconsolidation divestiture of FSA the Supply Chain Business in the prior year period (\$234 million), partially offset by lower selling, general and administrative expenses.

Operating loss increased \$221 million for the six months ended August 2, 2024 as compared to the same period in the prior year primarily due to the divestiture of the Supply Chain Business in the prior year (\$233 million) and the gain recognized from the deconsolidation of FSA (\$7 million), partially offset by lower selling, general and administrative expenses.

Non-GAAP Measures

Earnings before interest, taxes, depreciation and amortization ("EBITDA"), and adjusted EBITDA are non-GAAP financial measures. While we believe that these non-GAAP financial measures are also useful for management and investors in evaluating our financial information, they should be considered as supplemental in nature and not as a substitute for financial information prepared in accordance with GAAP.

Reconciliations, definitions, and how we believe these measures are useful to management and investors are provided below. Other companies may define similar measures differently.

-25-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

EBITDA and Adjusted EBITDA. The performance measure EBITDA is calculated by taking net income and excluding interest and loss on sale of receivables, provision for income taxes, and depreciation and amortization. Adjusted EBITDA is a performance measure that excludes costs that we do not consider to be indicative of our ongoing performance. Adjusted EBITDA is calculated by taking EBITDA and excluding acquisition and integration costs, impairments, restructuring costs, and any other material non-recurring costs. Integration costs are costs to integrate acquired companies including costs of strategic consulting services, facility consolidation and employee related costs such as retention and severance costs. The acquisition and integration costs relate to our acquisitions.

We believe that EBITDA and adjusted EBITDA provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding our long-term financial performance.

-24-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

EBITDA and adjusted EBITDA for the periods presented were calculated as follows:

	Three Months Ended		Six Months Ended	
	August 4, 2024		August 4, 2023	
	August 2, 2024	2023	August 2, 2024	2023
Net income				
Net income				
Net income				
Interest expense, net and loss on sale of receivables				
Interest expense, net and loss on sale of receivables				
Interest expense, net and loss on sale of receivables				
Provision for income taxes				
Provision for income taxes				
Provision for income taxes				
Depreciation and amortization				
Depreciation and amortization				
Depreciation and amortization				
EBITDA				
EBITDA				
EBITDA				
<i>EBITDA as a percentage of revenues</i>	<i>9.3 %</i>	<i>22.5 %</i>	<i>9.2 %</i>	<i>15.6 %</i>
<i>EBITDA as a percentage of revenues</i>				
<i>EBITDA as a percentage of revenues</i>				
Acquisition and integration costs ⁽¹⁾				
Acquisition and integration costs ⁽¹⁾				
Acquisition and integration costs ⁽¹⁾				
Restructuring and impairment costs				
Restructuring and impairment costs				
Restructuring and impairment costs				
Recovery of acquisition and integration costs and restructuring and impairment costs ⁽²⁾				
Recovery of acquisition and integration costs and restructuring and impairment costs ⁽²⁾				
Recovery of acquisition and integration costs and restructuring and impairment costs ⁽²⁾				
(Gain) loss on divestitures, net of transaction costs				
(Gain) loss on divestitures, net of transaction costs				
(Gain) loss on divestitures, net of transaction costs				
Adjusted EBITDA				
Adjusted EBITDA				
Adjusted EBITDA				
<i>Adjusted EBITDA as a percentage of revenues</i>	<i>9.4 %</i>	<i>9.8 %</i>	<i>9.2 %</i>	<i>9.5 %</i>
<i>Adjusted EBITDA as a percentage of revenues</i>				

Adjusted EBITDA as a percentage of revenues

- (1) Adjustment consists of a reversal of immaterial costs related to the Koverse acquisition.
- (2) Adjustment reflects the portion of acquisition and integration costs and restructuring and impairment costs recovered through our indirect rates in accordance with U.S. government Cost Accounting Standards.

Adjusted EBITDA as a percentage of revenues for the three and six months ended **May 3, 2024** **August 2, 2024** decreased compared to 9.0% from 9.3% the same periods in the prior year period, primarily due to contract completions, partially offset by ramp up in volume on existing and new contracts.contracts.

Other Key Performance Measures

In addition to the financial measures described above, we believe that bookings and backlog are useful measures for management and investors to evaluate our potential future revenues. We also consider measures such as contract types and cost of revenues mix to be useful for management and investors to evaluate our operating income and performance.

Net Bookings and Backlog. Net bookings represent the estimated amount of revenues to be earned in the future from funded and negotiated unfunded contract awards that were received during the period, net of adjustments to estimates on previously awarded contracts. We calculate net bookings as the period's ending backlog plus the period's revenues less the prior period's ending backlog and initial backlog obtained through acquisitions.

-26-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts as work is performed. We do not include in backlog estimates of revenues to be derived from IDIQ contracts, but rather record backlog and bookings when task orders are awarded on these contracts. Given that much of our revenue is derived from IDIQ contract task orders that renew annually, bookings on these contracts tend to refresh annually as the task orders are renewed. Additionally, we do not include in backlog contract awards that are under protest until the protest is resolved in our favor.

We segregate our backlog into two categories as follows:

- *Funded Backlog.* Funded backlog for contracts with government agencies primarily represents estimated amounts of revenue to be earned in the future from contracts for which funding is appropriated less revenues previously recognized on these contracts. It does not include the unfunded portion of contracts in which funding is incrementally appropriated or authorized on a quarterly or annual basis by the U.S. government and other customers even though the contract may call for performance over a number of years. Funded backlog for contracts with non-government customers represents the estimated value on contracts, which may cover multiple future years, under which we are obligated to perform, less revenues previously recognized on these contracts.

-25-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

- *Negotiated Unfunded Backlog.* Negotiated unfunded backlog represents estimated amounts of revenue to be earned in the future from negotiated contracts for which funding has not been appropriated or otherwise authorized and from unexercised priced contract options. Negotiated unfunded backlog does not include any estimate of future potential task orders expected to be awarded under IDIQ, GSA Schedules or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not

competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders.

We expect to recognize revenue from a substantial portion of our funded backlog within the next twelve months. However, the U.S. government can adjust the scope of services of or cancel contracts at any time. Similarly, certain contracts with commercial customers include provisions that allow the customer to cancel prior to contract completion. Most of our contracts have cancellation terms that would permit us to recover all or a portion of our incurred costs and fees (contract profit) for work performed.

The estimated value of our total backlog as of the dates presented was:

	May 3, 2024		February 2, 2024		August 2, 2024			February 2, 2024									
	Defense and Intelligence	Defense and Civilian	Total SAIC	Defense and Intelligence	Civilian	Total SAIC	Defense and Intelligence	Civilian	Total SAIC	Defense and Civilian	Total SAIC						
	(in millions)						(in millions)										
Funded backlog																	
Negotiated unfunded backlog																	
Total backlog																	

We had net bookings worth an estimated \$2.6 billion \$1.2 billion and \$3.8 billion during the three and six months ended May 3, 2024 August 2, 2024.

Contract Types. Our earnings and profitability may vary materially depending on changes in the proportionate amount of revenues derived from each type of contract. For a discussion of the types of contracts under which we generate revenues, see "Business - Contract Types" in Part I, Item 1 of the most recently filed Annual Report on Form 10-K. The following table summarizes revenues by contract type as a percentage of each reportable segment and total SAIC revenues for the periods presented:

	Three Months Ended May 3, 2024		
	Defense and Intelligence	Civilian	Total SAIC
	(in millions)		
Cost reimbursement	79 %	5 %	62 %
Time and materials ("T&M")	10 %	65 %	23 %
Firm-fixed price ("FFP")	11 %	30 %	15 %
Total	100 %	100 %	100 %
	Defense and Intelligence	Civilian	Total SAIC
	(in millions)		
Cost reimbursement	68 %	5 %	55 %
Time and materials ("T&M")	7 %	59 %	18 %
Firm-fixed price ("FFP")	25 %	36 %	27 %
Total	100 %	100 %	100 %

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

	Three Months Ended					
	August 2, 2024			August 4, 2023		
	Defense and Intelligence	Civilian	Total SAIC	Defense and Intelligence	Civilian	Total SAIC
	(in millions)					
Cost reimbursement	77 %	5 %	61 %	79 %	3 %	62 %
Time and materials ("T&M")	11 %	66 %	23 %	8 %	62 %	20 %

Firm-fixed price ("FFP")	12 %	29 %	16 %	13 %	35 %	18 %
Total	100 %	100 %	100 %	100 %	100 %	100 %
Six Months Ended						
	August 2, 2024			August 4, 2023		
	Defense and Intelligence	Civilian	Total SAIC	Defense and Intelligence	Civilian	Total SAIC
	(in millions)					
Cost reimbursement	78 %	5 %	62 %	73 %	4 %	58 %
Time and materials ("T&M")	11 %	65 %	23 %	8 %	60 %	19 %
Firm-fixed price ("FFP")	11 %	30 %	15 %	19 %	36 %	23 %
Total	100 %	100 %	100 %	100 %	100 %	100 %

The change in contract mix for the **three** **six** months ended **May 3, 2024** **August 2, 2024** is primarily due to a decrease in firm-fixed price type contracts due to the divestiture of the Supply Chain Business in the prior year, which historically had a higher proportion of these contracts.

-26-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Cost of Revenues Mix. We generate revenues by providing a customized mix of services to our customers. The profit generated from our service contracts is affected by the proportion of cost of revenues incurred from the efforts of our employees (which we refer to below as labor-related cost of revenues), the efforts of our subcontractors and the cost of materials used in the performance of our service obligations under our contracts. Contracts performed with a higher proportion of SAIC labor are generally more profitable. The following table presents cost mix as a percentage of each reportable segment and total SAIC revenues for the periods presented:

Three Months Ended May 3, 2024				Three Months Ended				
		August 2, 2024				August 4, 2023		
	Defense and Intelligence	Defense and Intelligence	Total Civilian SAIC		Defense and Intelligence	Total Civilian SAIC	Defense and Intelligence	Total Civilian SAIC
(in millions)								
Labor-related cost of revenues	Labor-related cost of revenues	58 %	59 %	58 %	Labor-related cost of revenues	56 %	59 %	56 %
Subcontractor-related cost of revenues	Subcontractor-related cost of revenues	30 %	30 %	30 %	Subcontractor-related cost of revenues	29 %	33 %	30 %
Other materials-related cost of revenues	Other materials-related cost of revenues	12 %	11 %	12 %	Other materials-related cost of revenues	15 %	8 %	14 %
Total	Total	100 %	100 %	100 %	Total	100 %	100 %	100 %
Three Months Ended May 5, 2023				Six Months Ended				
	August 2, 2024			August 4, 2023				

Defense and Intelligence		Defense and Intelligence		Total SAIC	Defense and Intelligence		Total Civilian SAIC		Defense and Intelligence		Total Civilian SAIC
				(in millions)			(in millions)				(in millions)
Labor-related cost of revenues	Labor-related cost of revenues	50 %	56 %	52 %	Labor-related cost of revenues	57 %	59 %	57 %	53 %	58 %	54 %
Subcontractor-related cost of revenues	Subcontractor-related cost of revenues	28 %	33 %	29 %	Subcontractor-related cost of revenues	29 %	32 %	30 %	29 %	34 %	30 %
Supply chain materials-related cost of revenues	Supply chain materials-related cost of revenues	11 %	— %	8 %	Supply chain materials-related cost of revenues	— %	— %	— %	5 %	— %	4 %
Other materials-related cost of revenues	Other materials-related cost of revenues	11 %	11 %	11 %	Other materials-related cost of revenues	14 %	9 %	13 %	13 %	8 %	12 %
Total	Total	100 %	100 %	100 %	Total	100 %	100 %	100 %	100 %	100 %	100 %

The change in cost of revenues mix for the three six months ended May 3, 2024 August 2, 2024 is primarily due to a decrease in supply chain materials-related costs due to the divestiture of the Supply Chain Business in the prior year.

-28-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Liquidity and Capital Resources

As a services provider, our business generally requires minimal infrastructure investment. We expect to fund our ongoing working capital, commitments and any other discretionary investments with cash on hand, future operating cash flows and, if needed, borrowings under our \$1.0 billion Revolving Credit Facility and \$300 million MARPA Facility.

We anticipate that our future cash needs will be for working capital, capital expenditures, and contractual and other commitments. We consider various financial measures when we develop and update our capital deployment strategy, which include evaluating cash provided by operating activities, free cash flow and financial leverage.

Our ability to fund these needs will depend, in part, on our ability to generate cash in the future, which depends on our future financial results. Our future results are subject to general economic, financial, competitive, legislative and regulatory factors that may be outside of our direct control. Although we believe that the financing arrangements in place will permit us to finance our operations on acceptable terms and conditions for at least the next year, our future access to, and the availability of financing on acceptable terms and conditions will be impacted by many factors (including our credit rating, capital market liquidity and overall economic conditions). Therefore, we cannot ensure that such financing will be available to us on acceptable terms or that such financing will be available at all. Nevertheless, we believe that our existing cash on hand, generation of future operating cash flows, and access to bank financing and capital markets will provide adequate resources to meet our short-term liquidity and long-term capital needs.

During the first quarter of fiscal 2025, we amended our Credit Facility. See Note 7—Debt Obligations to the condensed consolidated financial statements contained within this report for additional information.

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Historical Cash Flow Trends

The following table summarizes our cash flows:

	Three Months Ended		Six Months Ended	
	May 3, 2024	May 5, 2023	August 2, 2024	August 4, 2023
			(in millions)	(in millions)
Net cash provided by operating activities				

Net cash (used in) provided by investing activities

Net cash used in financing activities

Net (decrease) increase in cash, cash equivalents and restricted cash

Net Cash Provided by Operating Activities. Refer to "Results of Operations" above for a discussion of the changes in cash flows provided by operating activities between increased \$4 million for the three six months ended May 3, 2024 and August 2, 2024 as compared to the comparable prior year period. primarily due to timing of customer collections and vendor payments, lower tax payments in the current year, and other net favorable changes in working capital, partially offset by higher incentive-based compensation payments and higher cash used from the Master Accounts Receivable Purchase Agreement ("MARPA Facility") in the current year (see Note 10—Sales of Receivables to the condensed consolidated financial statements contained within this report for additional information).

Net Cash (Used in) Provided by Investing Activities. Cash used in investing activities for the three six months ended May 3, 2024 August 2, 2024 was \$7 \$16 million compared to cash provided by investing activities of \$336 \$334 million in the prior year period. This change is primarily due to the \$355 million of cash proceeds for the sale of the Supply Chain Business in the prior year period (see Note 4 to the condensed consolidated financial statements).

Net Cash Used in Financing Activities. Cash used in financing activities for the three six months ended May 3, 2024 increased August 2, 2024 decreased compared to the prior year period primarily due to higher principal payments, net of proceeds received from borrowings, and net of principal payments, partially offset by higher share repurchases in the current year.

Critical Accounting Policies and Estimates

There have been no changes to our critical accounting policies and estimates during the three six months ended May 3, 2024 August 2, 2024 from those disclosed in our most recently filed Annual Report on Form 10-K.

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Recently Issued But Not Yet Adopted Accounting Pronouncements

For information on recently issued but not yet adopted accounting pronouncements, see Note 1 to the condensed consolidated financial statements contained within this report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes to our market risks from those discussed in our most recently filed Annual Report on Form 10-K.

Item 4. Controls and Procedures

Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) and have concluded that as of **May 3, 2024** **August 2, 2024** these controls and procedures were operating and effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarterly period covered by this report which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

-28- -30-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

We have provided information about legal proceedings in which we are involved in our fiscal 2024 Annual Report on Form 10-K, and we have provided an update to this information in Note 12—Legal Proceedings and Other Commitments and Contingencies to the condensed consolidated financial statements contained within this report, which is incorporated herein by reference.

In addition to the described legal proceedings, we are routinely subject to investigations and reviews relating to compliance with various laws and regulations. Additional information regarding such investigations and reviews is included in our fiscal 2024 Annual Report on Form 10-K, and we have also updated this information in Note 12—Legal Proceedings and Other Commitments and Contingencies to the condensed consolidated financial statements contained within this report, under the heading “Government Investigations, Audits and Reviews,” which is incorporated herein by reference.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in our most recently filed Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds and Issuer Purchases of Equity Securities

Purchases of Equity Securities. We may repurchase shares on the open market in accordance with established repurchase plans. Whether repurchases are made and the timing and amount of repurchases depend on a variety of factors including market conditions, our capital position, internal cash generation and other factors. We also repurchase shares in connection with stock option and stock award activities to satisfy tax withholding obligations.

The following table presents repurchases of our common stock during the three months ended **May 3, 2024** **August 2, 2024**:

Period ⁽¹⁾	Total Number of Shares (or Units) Purchased ⁽²⁾	Average Price Paid per Share (or Unit)	Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs ⁽³⁾
February 3, 2024 - March 8, 2024	224,038	\$ 135.86	223,732	3,954,245
March 9, 2024 - April 5, 2024	183,855	131.86	183,534	3,770,711
April 6, 2024 - May 3, 2024	204,535	127.22	204,535	3,566,176
Total	612,428	\$ 131.77	611,801	

Period ⁽¹⁾	Total Number of Shares (or Units) Purchased ⁽²⁾	Average Price Paid per Share (or Unit)	Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs ⁽³⁾
May 4, 2024 - June 7, 2024	269,779	\$ 129.67	268,906	3,297,270
June 8, 2024 - July 5, 2024	390,280	116.08	390,280	2,906,990
July 6, 2024 - August 2, 2024	1,016,832	119.14	1,015,737	1,891,253
Total	1,676,891	\$ 120.12	1,674,923	

(1) Date ranges represent our fiscal periods during the current quarter. Our fiscal quarters typically consist of one five-week period and two four-week periods.

(2) Includes shares purchased on surrender by stockholders of previously owned shares to satisfy minimum statutory tax withholding obligations related to stock option exercises and vesting of stock awards in addition to shares purchased under our publicly announced plans or programs.

(3) In June 2022, the number of shares that may be purchased increased by 8.0 million shares, bringing the total authorized shares to be repurchased under the plan to approximately 24.4 million shares. As of **May 3, 2024** **August 2, 2024**, we have repurchased approximately **20.9 million** **22.6 million** shares of common stock under the program.

Item 3. Defaults Upon Senior Securities

No information is required in response to this item.

Item 4. Mine Safety Disclosures

No information is required in response to this item.

Item 5. Other Information

During the three months ended **May 3, 2024** **August 2, 2024**, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," as such terms are defined in Item 408 of Regulation S-K.

-29- -31-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Item 6. Exhibits

Exhibit	Number	Description of Exhibit
	<u>10.1*</u>	<u>First Amendment to the Science Applications International Corporation 2023 Equity Incentive Plan, effective March 5, 2024.</u>
	<u>10.2*</u>	<u>First Amendment to the Science Applications International Corporation Amended and Restated 2013 Employee Stock Purchase Plan, effective March 5, 2024.</u>
	<u>10.3</u>	<u>Sixth Amendment to the Third Amended and Restated Credit Agreement, dated February 8, 2024, by and among SAIC, Citibank N.A., as administrative agent and collateral agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on February 12, 2024.</u>
	<u>31.1</u>	<u>Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
	<u>31.2</u>	<u>Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
	<u>32.1</u>	<u>Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
	<u>32.2</u>	<u>Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101		Interactive Data File. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104		The cover page from this Quarterly Report on Form 10-Q, formatted as Inline XBRL.

* Management contract or compensatory plan or agreement.

-30- -32-

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 3, 2024 September 5, 2024

Science Applications International Corporation

/s/ Prabu Natarajan

Prabu Natarajan
Executive Vice President and Chief Financial Officer

-31-

**AMENDMENT NO. 1
TO THE
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
2023 EQUITY INCENTIVE PLAN**

WHEREAS, Science Applications International Corporation (the “Company”) maintains the Science Applications International Corporation 2023 Equity Incentive Plan (the “Plan”); and

WHEREAS, the Company wishes to amend the Plan to reflect the change in the Company’s listing from the New York Stock Exchange to The Nasdaq Stock Market LLC which will be effective March 5, 2024;

NOW, THEREFORE, BE IT RESOLVED, that the Plan be, and it hereby is, amended as follows:

1. Effective March 5, 2024, Subsection 2(b), the definition of “Applicable Law” is hereby deleted and replaced with the following:

(b) “Applicable Law” means any and all laws of whatever jurisdiction, within or without the United States, and the rules of any stock exchange or quotation system on which Shares are then listed or quoted, applicable to the taking or refraining from taking of any action under the Plan, including the administration of the Plan and the issuance or transfer of Awards or Shares.
2. Effective as of March 5, 2024, the first sentence of Subsection 2(t), the definition of “Fair Market Value” is hereby deleted and replaced with the following:

(t) “Fair Market Value” means, as of any Value Date, the closing sales price as quoted for a Share on the New York Stock Exchange or The Nasdaq Stock Market LLC (as applicable) for the day before the Value Date, as reported in The Wall Street Journal or a similar publication.

Approved by the Human Resources and Compensation Committee on March 26, 2024.

US.362859131.01

**AMENDMENT NO. 1
TO THE
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
2013 EMPLOYEE STOCK PURCHASE PLAN**

WHEREAS, Science Applications International Corporation (the “Company”) maintains the Science Applications International Corporation 2013 Employee Stock Purchase (the “Plan”) which was amended and restated effective June 7, 2023; and

WHEREAS, the Company wishes to amend the Plan to reflect the change in the Company's listing from the New York Stock Exchange to The Nasdaq Stock Market LLC which will be effective March 5, 2024;

NOW, THEREFORE, BE IT RESOLVED, that the Plan be, and it hereby is, amended as follows:

1. Effective March 5, 2024, the first sentence of Subsection 2(j), the definition of "Fair Market Value" is hereby deleted and replaced with the following:

(j) "Fair Market Value" means, as of any Value Date, the closing sales price as quoted for a Share on the New York Stock Exchange or The Nasdaq Stock Market LLC (as applicable) for the day before the Value Date, as reported in The Wall Street Journal or a similar publication.

Approved by the Human Resources and Compensation Committee on March 26, 2024.

US.362860200.01-33

Exhibit 31.1

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Toni Townes-Whitley, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended **May 3, 2024** **August 2, 2024** of Science Applications International Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **June 3, 2024** **September 5, 2024**

/s/ Toni Townes-Whitley

Toni Townes-Whitley
Chief Executive Officer

Exhibit 31.2

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Prabu Natarajan, certify that:

- I have reviewed this Quarterly Report on Form 10-Q for the period ended **May 3, 2024** **August 2, 2024** of Science Applications International Corporation;
- Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **June 3, 2024** **September 5, 2024**

/s/ Prabu Natarajan

Prabu Natarajan

Chief Financial Officer

Exhibit 32.1

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
18 U.S.C SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Science Applications International Corporation (the "Company") on Form 10-Q for the period ended **May 3, 2024** **August 2, 2024** as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Toni Townes-Whitley, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: **June 3, 2024** **September 5, 2024**

/s/ Toni Townes-Whitley

Toni Townes-Whitley

Chief Executive Officer

SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
18 U.S.C SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Science Applications International Corporation (the "Company") on Form 10-Q for the period ended **May 3, 2024** **August 2, 2024** as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Prabu Natarajan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: **June 3, 2024** **September 5, 2024**

/s/ Prabu Natarajan

Prabu Natarajan
Chief Financial Officer

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.